Wall Street Zen Downgrades Collegium Pharmaceutical to 'Buy' Rating

Analysts cite mixed Q4 earnings results as reason for rating change.

Feb. 28, 2026 at 7:07am

Got story updates? Submit your updates here. ›

Collegium Pharmaceutical (NASDAQ:COLL), a specialty pharmaceutical company focused on pain management and opioid dependence treatments, was downgraded from a 'strong-buy' to a 'buy' rating by analysts at Wall Street Zen. The downgrade comes after the company reported Q4 earnings that slightly missed consensus estimates, despite recording record full-year revenues.

Why it matters

Collegium Pharmaceutical's stock has been volatile in recent months as investors weigh the company's growth prospects against concerns around profit margins and earnings consistency. The analyst downgrade, while still maintaining a 'buy' rating, signals some uncertainty around the near-term outlook for the company.

The details

In its research note, Wall Street Zen cited Collegium's Q4 earnings miss as the primary driver behind the rating change. The company reported earnings per share of $2.04, below the $2.20 expected by analysts. Q4 revenue of $205.4 million also came in slightly below estimates. However, Collegium did report record full-year 2026 net revenues of $780.6 million, up 24% year-over-year.

  • Collegium Pharmaceutical reported Q4 2026 earnings on February 26, 2026.
  • Wall Street Zen downgraded the stock to a 'buy' rating on February 28, 2026.

The players

Collegium Pharmaceutical

A specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence.

Wall Street Zen

A stock research and analysis firm that recently downgraded Collegium Pharmaceutical from a 'strong-buy' to a 'buy' rating.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

Collegium Pharmaceutical's mixed Q4 results have prompted some uncertainty around the company's near-term outlook, leading analysts to take a more cautious stance. However, the company's record full-year revenues and growth in its lead product Jornay PM suggest longer-term potential, despite the recent earnings miss.